Colin Bicknell
Professor of Vascular Surgery
Imperial College Healthcare NHS Trust
London, UK
Colin Bicknell is a Consultant Vascular Surgeon and Professor of Vascular Surgery at the Imperial Vascular Unit, London.
He is clinical lead for the National Vascular Registry, chair of the audit and quality improvement committee for the Vascular Society of Great Britain and Ireland, co-chair of the Aortic Special Interest Group to lead patient prioritised aortic research in the UK. He is a council member of the Vascular Society of Great Britain and Ireland.
Professor Bicknell is the past-President of the British Society of Endovascular Therapy and past-Chair of The Aortic Dissection Charitable Trust Research Advisory Group.
He directs a translational aortic clinical research programme, leading research trials, including the NIHR funded EARNEST trial, a multicentre long-term trial of the benefits of early stenting after acute uncomplicated type-B aortic dissection.
He is a member of the Editorial Boards for the European Journal of Vascular and Endovascular Surgery and the Journal of Endovascular Therapy. He is the Course Director of the Imperial Health Policy MSc for nearly ten years and has overseen the graduation of over 300 students.
Talks
14:40 to 15:10
Interactive MDT simulation in conjunction with the European Vascular Course
Chair: Barend Mees
Cases for discussion: Becky Sandford & Mohamed Abdelhalim
Expert panel: Judith Partridge, Panos Gkoutzios, Eric Roselli, Colin Bicknell, Michael Sabetai, Stephen Cheng
Barend Mees, Becky Sandford, Jude Partridge, Panos Gkoutzios, Eric Roselli, Colin Bicknell, Michael Sabetai, Stephen Cheng15:50 to 16:10
Global roundtable on evidence for managing uncomplicated Type B dissection
3 minute update on uncomplicated TBAD trials
Moderator: Kevin Mani
Panel: Firas Mussa, Colin Bicknell, Jacob Budtz-Lilly
Discussion points:
- Medical optimisation, how is this being achieved in practice in the trials?
- Does device choice and timing of intervention really change outcomes?
- What are we learning from the patients not included in the trials? Data from screening
- How generalisable are these trials - management of dissections and centres of expertise